ARON-2 Study-Multicentric International Retrospective Study
Recruiting
Observational Study
Urothelial Carcinoma
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 367 (estimated)
- Sponsor
- Matteo Santoni · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The ARON-2 study retrospectively analyze patients treated with pembrolizumab as first-line therapy in patients platinum-unfit or as second-line therapy in patients progressed after previous platinum-based chemotherapy. The amendment has been designed to also analyze patients treated with enfortumab vedotin progressed to previous platinum-based chemotherapy and anti-PD-1/PD-L1 inhibitor.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients aged \>18y
* Histologically confirmed diagnosis of UC of upper and/or lower urinary tract
* Histologically or radiologically confirmed metastatic disease
* Patients treated with at least one of the following:
* Treatment with pembrolizumab in patients progressed after…
Contacts